Sigyn Therapeutics CEO Jim Joyce joined Steve Darling from Proactive to discuss the company’s latest advancements in infectious disease treatments with their lead product, Sigyn Therapy. This cutting-edge blood purification technology is designed to treat a wide range of conditions, including drug-resistant infections, viral pathogens, and life-threatening illnesses such as sepsis. Having successfully completed preclinical stages, Sigyn is now preparing for its first-in-human clinical trials.
Joyce highlighted the strategic importance of navigating the U.S. FDA regulatory process, noting, “The FDA is the gold standard globally, and if we can execute here in the U.S., other markets open up much more easily.” Sigyn Therapy also targets bacterial toxins and pro-inflammatory conditions, offering significant potential for improving outcomes in patients on dialysis, who face high mortality rates.
The first clinical trial will focus on patients with end-stage renal disease suffering from Endotoxemia, a condition closely associated with dialysis-related mortality. Joyce emphasized that Sigyn’s technology aims to address critical unmet needs in treating infectious diseases and inflammatory conditions, especially for patients underserved by conventional drug therapies.
#proactiveinvestors #sigyntherapeuticsinc #otcqb #sigy #SigynTherapeutics #InfectiousDiseases
#BloodPurification #FDAApproval #SepsisTreatment #MedicalTechnology #HealthcareInnovation #RenalDisease #LifeSciences
#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews